27results about "Somatostatins" patented technology

The present application relates to animals or cells having a myostatin gene with a 12 base pair deletion in the second exon. The application may also include compositions capable of engineering a 12 base pair deletion in the myostatin gene to construct animals or cells. The application also relates to the use of the compositions to increase muscle mass.

The present invention relates to fusion proteins that agonise a somatostatin receptor (SSTR), in particular somatostatin receptor 4 (SSTR4), and methods for producing the same. The fusion proteins of the invention comprise a scaffold and a somatostatin (SST)-derived peptide and, optionally, a partner domain.

The present invention relates to novel structures, synthesis methods, and applications of human somatostatin analogs comprising either a cyclic or non-cyclic hexapeptide unit, wherein the amino acid residues at positions 2 to 5 are represented by -X1-(D / L)-Trp-X2-X3-, or a cyclic or non-cyclic octapeptide unit, wherein the amino acid residues at positions 2 to 7 are represented by -Cys-X1-(D / L)-Trp-X2-X3-Cys-. In these sequences, X1 is an α-amino acid residue containing an aromatic group on the Cα side chain, X2 is a Lys derivative, and X3 is an α-amino acid residue. The Lys derivative has the following structure: wherein n is 0 or 1; A1, A2, and A3 are independently selected from C(R)2, O, S, NR, C=O, C=S, C=NR, and C=C(R)2. The present invention challenges the conventional understanding that modification of the Lys9 residue in somatostatin significantly reduces biological activity. By altering the Lys9 residue in somatostatin analogs, the present invention provides analogs with enhanced or comparable binding affinity to SSTR2, thereby improving their therapeutic efficacy.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

The present application relates to an animal or cell having a myostatin gene in which 12 base pairs of the second exon are deleted. The present application may also comprise a composition capable of manipulating the deletion of 12 base pairs of a myostatin gene to construct the animal or the cell. The present application also relates to use of the composition for increasing muscle.

The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue via 18F-labeled peptide ligands disclosed herein.

To provide effective, shelf-stable and safe biological preparations such as peptides and proteins for non-invasive delivery.SOLUTION: The present invention relates to a pharmaceutical composition for transmucosal administration, comprising a peptide drug or a protein drug in combination with an excipient with a pKa value of 12 or higher.SELECTED DRAWING: None

This application relates to animals or cells possessing a myostatin gene, wherein 12 base pairs of the second exon of the myostatin gene are deleted. This application may also include compositions capable of manipulating the deletion of 12 base pairs of the myostatin gene to construct animals or cells. This application also relates to the use of this composition for increasing muscle mass.

This invention provides a method for preparing sterile lanreotide raw material, comprising the following five steps: (1) preparing a lanreotide cyclic peptide solution; (2) purifying the lanreotide cyclic peptide solution once using HPLC, wherein the mobile phase A is an ammonium salt solution and the mobile phase B is an organic reagent; (3) purifying the once-purified lanreotide cyclic peptide solution a second time using HPLC, wherein the mobile phase A is a sodium salt solution and the mobile phase B is an organic reagent; (4) treating the second-purified lanreotide cyclic peptide solution with an aqueous acetic acid solution to obtain an acetate lanreotide solution; (5) filtering and drying the acetate lanreotide solution to obtain the finished product. The lanreotide raw material obtained by the preparation method of this invention has a purity greater than 99.9% and a single impurity content ≤0.10%.

A composition for modifying a myostatin gene, the composition comprising: a guide RNA; a Cas protein; wherein the target sequence is one selected from: SEQ ID NO: 38-60 and the guide sequence is one s

The present invention provides a use of a polypeptide complex on the basis of Titin-Telethonin beta-pleated sheet structure as a polypeptide or protein drug carrier, a method, and a fusion protein complex thereof. The polypeptide complex is capable of maintaining the activity of polypeptide or protein drugs and prolonging the half-life period simultaneously.

The present invention relates generally to the field of bioconjugation. More particularly, the present invention relates to trivalent phosphonates and their use as reducing disulfide heavy bridging agents. Accordingly, the present invention relates to compounds selected from the group consisting of compounds of formula (la) and (lb), conjugates obtained by linking these compounds to another moiety, methods of modifying disulfide containing compounds using compounds selected from the group consisting of compounds of formula (la) and (lb), and compounds obtained by such methods.

The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and treatment of diseases where either or both receptors are overexpressed.

The present invention relates to halogenated somatostatin analogs with selectivity for multiple somatostatin receptor subtypes and pharmaceutical compositions comprising the same. Moreover, the present invention relates to said halogenated somatostatin analogs and pharmaceutical compositions for use in therapy and / or diagnosis, for example in the treatment and / or diagnosis of diseases (e.g., cancer such as a neuroendocrine cancer) that are characterized by a high expression (e.g., overexpression) of one or more somatostatin receptor subtypes (e.g., somatostatin receptor 2 (SST2) and / or somatostatin receptor 5 (SST5)).

The invention relates to an adaptor molecule for targeting a cancer cell, comprising a somatostatin receptor 2 (SSTR2) targeting moiety, a linker moiety, and a tag moiety, wherein the SSTR2 targeting moiety is connected to the tag moiety by means of the linker moiety.

Described herein is a dual-functional tetrazine–allyl reagent that enables site-selective disulfide modification in peptides and proteins, serving both as a Michael acceptor for bis-thiols and as a reactive handle for Inverse Electron-Demand Diels–Alder (IEDDA) click chemistry to introduce functional payloads.

The present disclosure relates to methods of large scale synthesis of radionuclide complex solutions having a high activity for diagnostic and / or therapeutic purposes, their use in the commercial production of radioactive drug substances, and to respective solutions as well as containers comprising said solutions.

The present disclosure relates to methods for the large scale synthesis of radionuclide complex solutions having high radioactivity for diagnostic and / or therapeutic purposes, their use in the commercial manufacture of radiopharmaceutical substances, and to the respective solutions and containers containing said solutions.

The present invention relates to compounds comprising a metal chelator and two fragments capable of binding to type 2 somatostatin receptors, compositions thereof and uses thereof in methods of treatment.

To provide a pharmaceutical composition that allows extended release of cationic peptide.SOLUTION: A pharmaceutical composition contains an ionic composite containing cationic polypeptide and anionic excipient selected from PEG-carboxylic acid, fatty acid having 10 or more carbon atoms, anionic phospholipid, and a combination thereof.SELECTED DRAWING: None

The present application relates to an engineered cell, an engineered protomyostatin protein, compositions comprising the same, nucleic acids encoding the same, and methods of production thereof. The engineered cells comprise a myostatin gene that is artificially modified. In some embodiments, the engineered cell expresses less myostatin mRNA as compared to a wild type cell. In addition, the engineered cell can express a mature myostatin protein having the same amino acid sequence as a wild-type animal.

The present disclosure discloses a method for synthesizing an amide and / or a polypeptide using a temporary protected amino acid as an ammonia component. In the present disclosure, a ynamide compound is used as a condensing agent, a low-cost unprotected amino acid is used as the raw material, a silylation reagent is used to temporarily protect the amino acid to perform a condensing reaction, and after the construction of a peptide bond is achieved, a target polypeptide carboxylic acid can be obtained by a simple acid treatment, which can be directly used for the condensation of the next amino acid.

The present invention relates to an extruded depot for sustained release of an active agent comprising at least one active agent and at least one first compound from the class of biodegradable organic polymers based on lactic acid and / or glycolic acid.

The present invention relates to a method for treating small cell lung cancer (SCLC), particularly in a subject in need thereof, comprising administering to a subject a SSTR binding moiety, particularly 177 A therapeutically effective amount of a radiopharmaceutical compound comprising]Lu-DOTATE is administered to the subject in combination with one or more chemotherapeutic agents, such as carboplatin and etoposide, and optionally an immuno-oncology (I / O) agent, such as tislelizumab.

SOLUTION: Compositions and methods are disclosed for targeted delivery of therapeutic polypeptides and protein-based therapeutics across the gastrointestinal lining. In one embodiment, provided is a polypeptide construct comprising: (a) a first polypeptide, the first polypeptide comprising an amino acid sequence at least 80% identical to an amino acid sequence selected from any one of SEQ ID NOS: 1-40; and (b) a second polypeptide, the second polypeptide being heterologous to the first polypeptide. In one embodiment, the heterologous polypeptide is a therapeutic polypeptide.

The present invention relates to peptide conjugates of peptide tubulin inhibitors (e.g., monomethyl auristatin) that are useful in the treatment of diseases such as cancer.

The present invention relates to novel structures, synthesis methods, and applications of human somatostatin analogs comprising either a cyclic or non-cyclic hexapeptide unit, wherein the amino acid residues at positions 2 to 5 are represented by -X1-(D / L)-Trp-X2-X3-, or a cyclic or non-cyclic octapeptide unit, wherein the amino acid residues at positions 2 to 7 are represented by -Cys-X1-(D / L)-Trp-X2-X3-Cys-. In these sequences, X1 is an α-amino acid residue containing an aromatic group on the Cα side chain, X2 is a Lys derivative, and X3 is an α-amino acid residue. The Lys derivative has the following structure: wherein n is 0 or 1; A1, A2, and A3 are independently selected from C(R)2, O, S, NR, C=O, C=S, C=NR, and C=C(R)2. The present invention challenges the conventional understanding that modification of the Lys9 residue in somatostatin significantly reduces biological activity. By altering the Lys9 residue in somatostatin analogs, the present invention provides analogs with enhanced or comparable binding affinity to SSTR2, thereby improving their therapeutic efficacy.